4/A: Chromocell Therapeutics Director Amends Filing to Include IPO Share Purchase
SEC Filing
Ezra Friedberg, a director at Chromocell Therapeutics, amends a previous SEC Form 4 filing to include the purchase of 16,667 shares during the company's initial public offering (IPO).
Summary
- Ezra Friedberg, a director of Chromocell Therapeutics, filed an amended SEC Form 4 to report a transaction.
- The amendment includes the purchase of 16,667 shares of Chromocell Therapeutics common stock during the company's IPO.
- The shares were purchased at a price of $6 per share.
- Following the reported transaction, Friedberg directly owns 545,721 shares of Chromocell Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for company insiders (directors, officers, and 10% owners) to report transactions in their company's stock, providing transparency to the market.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 02/21/2024 | Date of original filing and earliest transaction date. |
| 03/12/2024 | Date of signature on the amended Form 4/A. |
Keywords
Form 4, Chromocell Therapeutics, Director, Ezra Friedberg, IPO, Share Purchase, Amendment, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.